Phase 1 SCB-313 for Malignant Pleural Effusion Treatment tested by Clover Biopharmaceuticals in Australia

According to an announcement by an international biotechnology company in China, Clover Biopharmaceuticals, thriving to develop new biological therapies, the first-ever cancer patient suffering from malignant pleural effusions was admitted in Australia in a fully human TRAIL-Trimer fusion protein...